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Future research and therapeutic applications of




There is much to be investigated about the specific characteristics of stem cells and about the efficacy and safety
of the new drugs based on this type of cells, both embryonic as adult stem cells, for several therapeutic indications
(cardiovascular and ischemic diseases, diabetes, hematopoietic diseases, liver diseases). Along with recent progress
in transference of nuclei from human somatic cells, as well as iPSC technology, has allowed availability of lineages
of all three germ layers genetically identical to those of the donor patient, which permits safe transplantation of
organ-tissue-specific adult stem cells with no immune rejection. The main objective is the need for expansion of
stem cell characteristics to maximize stem cell efficacy (i.e. the proper selection of a stem cell) and the efficacy
(maximum effect) and safety of stem cell derived drugs. Other considerations to take into account in cell therapy
will be the suitability of infrastructure and technical staff, biomaterials, production costs, biobanks, biosecurity, and
the biotechnological industry. The general objectives in the area of stem cell research in the next few years, are
related to identification of therapeutic targets and potential therapeutic tests, studies of cell differentiation and
physiological mechanisms, culture conditions of pluripotent stem cells and efficacy and safety tests for stem cell-
based drugs or procedures to be performed in both animal and human models in the corresponding clinical trials.
A regulatory framework will be required to ensure patient accessibility to products and governmental assistance for
their regulation and control. Bioethical aspects will be required related to the scientific and therapeutic relevance
and cost of cryopreservation over time, but specially with respect to embryos which may ultimately be used for
scientific uses of research as source of embryonic stem cells, in which case the bioethical conflict may be further
aggravated.
Introduction
A great interest has arisen in research in the field of
stem cells, which may have important applications in
tissue engineering, regenerative medicine, cell therapy,
and gene therapy because of their great therapeutic
potential, which may have important applications [1,2].
Cell therapy is based on transplantation of live cells
into an organism in order to repair a tissue or restore
lost or defective functions. Cells mainly used for such
advanced therapies are stem cells, because of their ability
to differentiate into the specific cells required for repair-
ing damaged or defective tissues or cells [3]. Regenerative
medicine is in turn a multidisciplinary area aimed at
maintenance, improvement, or restoration of cell, tissue,
or organ function using methods mainly related to cell
therapy, gene therapy, and tissue engineering.
There is however much to be investigated about the
specific characteristics of stem cells. The mechanisms by
which they differentiate and repair must be understood,
and more reliable efficacy and safety tests are required
for the new drugs based on stem cells.
General aspects of stem cells
The main properties that characterize stem cells include
their indefinite capacity to renew themselves and leave
their initial undifferentiated state to become cells of sev-
eral lineages. This is possible because they divide sym-
metrically and/or asymmetrically, i.e. each stem cell
results in two daughter cells, one of which preserves its
potential for differentiation and self-renewal, while the
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other cell directs itself toward a given cell lineage, or
they both retain their initial characteristics.
Stem cells are able to renew themselves and produce
mature cells with specific characteristics and functions
by differentiating in response to certain physiological sti-
muli. Different types of stem cells are distinguished
based on their potential and source. These include the
so-called totipotent embryonic cells, which appear in the
early stages of embryo development, before blastocyst
formation, capable of forming a complete organism, as
well as all intra and extra embryonic tissues. There are
also pluripotent embryonic cells, which are able to dif-
ferentiate into any type of cell, but not into the cells
forming embryonic structures such as placenta and
umbilical cord. Multipotent adult cells (such as hemato-
poietic cells, which may differentiate into platelets, red
blood cells, or white blood cells) are partially specialized
cells but are able to form a specific number of cell
types. Unipotent cells only differentiate into a single cell
lineage, are found in the different body tissues, and their
function is to act as cell reservoirs in the different tis-
sues. Germ stem cells are pluripotent embryonic stem
cells derived from gonadal buds of the embryo which,
after a normal embryonic development, will give rise to
oocytes and spermatozoa [4,5].
In the fetal stage there are also stem cells with differ-
entiation and self-renewal abilities. These stem cells
occur in fetal tissues and organs such as blood, liver,
and lung and have similar characteristics to their coun-
terparts in adult tissues, although they show a greater
capacity to expand and differentiate [6]. Their origin
could be in embryonic cells or in progenitors unrelated
to embryonic stem cells.
Adult stem cells are undifferentiated cells occurring in
tissues and organs of adult individuals which are able to
convert into differentiated cells of the tissue where they
are. They thus act as natural reservoirs for replacement
cells which are available throughout life when any tissue
damage occurs. These cells occur in most tissues,
including bone marrow, trabecular bone, periosteum,
synovium, muscle, adipose tissue, breast gland, gastroin-
testinal tract, central nervous system, lung, peripheral
blood, dermis, hair follicle, corneal limbus, etc. [7].
In most cases, stem cells from adult tissues are able to
differentiate into cell lineages characteristics of the niche
where they are located, such as stem cells of the central
nervous system, which generate neurons, oligodendro-
cytes, and astrocytes. Some unipotent stem cells, such as
those in the basal layer of interfollicular epidermis (pro-
ducing keratinocytes) or some adult hepatocytes, may
even have a repopulating function in the long term [8].
Adult stem cells have some advantages in terms of
clinical applications over embryonic and induced pluri-
potent stem cells because their use poses no ethical
conflicts nor involves immune rejection problems in the
event of autologous implantation, but induced pluripo-
tent stem cells are at least, if not more capable than
those from adult (stem) cells.
Mesenchymal stem cells
Although adult stem cells are primarily unipotent cells,
under certain conditions they show a plasticity that causes
them to differentiate into other cell types within the same
tissue. Such capacity results from the so-called transdiffer-
entiation in the presence of adequate factors–as occurs in
mesenchymal stem cells, which are able to differentiate
into cells of an ectodermal (neurons and skin) and endo-
dermal (hepatocytes, lung and intestinal cells) origin–or
from the cell fusion process, such as in vitro fusion of
mesenchymal stem cells with neural progenitors or in vivo
fusion with hepatocytes in the liver, Purkinje neurons in
the brain, and cardiac muscle cells in the heart [9].
This is why one of the cell types most widely used to
date in cell therapy are mesenchymal stem cells (MSCs),
which are of a mesodermal origin and have been iso-
lated from bone marrow, umbilical cord blood, muscle,
bone, cartilage, and adipose tissue [10]. From the experi-
mental viewpoint, the differential characteristics of
MSCs include their ability to adhere to plastic when
they are cultured in vitro; the presence of surface mar-
kers typical of mesenchymal cells (proteins such as
CD105, CD73, and CD90) and the absence of markers
characteristic of hematopoietic cells, monocytes, macro-
phages, or B cells; and their capacity to differentiate in
vitro under adequate conditions into at least osteoblasts,
adipocytes, and chondroblasts [11,12].
Recent studies have shown that MSCs support hema-
topoiesis and immune response regulation [13]. They
also represent an optimum tool in cell therapy because
of their easy in vitro isolation and expansion and their
high capacity to accumulate in sites of tissue damage,
inflammation, and neoplasia. MSCs are therefore useful
in regenerative therapy, in graft-versus-host disease and
in Crohn’s disease, or in cancer therapy [14-17].
The development in the future of an optimum metho-
dology for genetic manipulation of MSCs may even
increase their relevant role in cell and gene therapy [18].
Adipose-derived mesenchymal stem cells
Bone marrow has been for years the main source of
MSCs, but bone marrow harvesting procedure is uncom-
fortable for the patient, the amount of marrow collected
is scarce, and the proportion of MSCs it contains as com-
pared to the total population of nucleated cells is very
low (0.001%-0.01%) [19]. By contrast, subcutaneous adi-
pose tissue is usually abundant in the body and is a waste
product from the therapeutic and cosmetic liposuctions
increasingly performed in Western countries. These are
simple, safe, and well tolerated procedures, with a com-
plication rate of approximately 0.1%, where an amount of
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fat ranging from a few hundreds of milliliters to several
liters (up to 3 liters, according to the recommendation of
the World Health Organization) is usually drawn and
subsequently discarded. Despite the suction forces
exerted during aspiration, it is estimated that 98%-100%
of tissue cells are viable after extraction. The liposuction
method is therefore the most widely accepted for MSCs
collection [20,21].
Adipose-derived stem cells (ASCs) were first identified
in 2001 by Zuk et al. [22]. In addition to having the dif-
ferentiation potential and self-renewal ability character-
istic of MSCs, these cells secrete many cytokines and
growth factors with anti-inflammatory, antiapoptotic,
and immunomodulatory properties such as vascular
endothelial growth factor (VEGF), hepatocyte growth
factor (HGF), and insulin-like growth factor-1 (IGF-1),
involved in angiogenesis, healing, and tissue repair pro-
cesses [23]. This ability to secrete proangiogenic cyto-
kines makes ASCs optimum candidates for cell therapy
of ischemic diseases. In this regard, in a lower limb
ischemia model in rats, intravenous or intramuscular
ASCs administration was reported to significantly
improve blood flow, probably due to the direct effect of
ASCs differentiation into endothelial cells, and to the
indirect effect of secretion of growth factors that pro-
mote neovascularization [24,25].
The immunomodulatory properties of ASCs and their
lack of expression of MHC class II antigens also make
them adequate for allogeneic transplantation, minimiz-
ing the risk of rejection. ASCs regulate T cell function
by promoting induction of suppressor T cells and inhi-
biting production of cytotoxic T cells, NK cells, and
proinflammatory cytokines such as tumor necrosis fac-
tor-a (TNF-a), interferon-g (IFN-g), and interleukine-12
(IL-12). These effects, complemented by secretion of
soluble factors such as IL-10, transforming growth fac-
tor-b (TGF-b) and prostaglandin E2, account for the
immunosuppressive capacity of these cells, which was
demonstrated in a clinical trial where graft-versus-host
disease (GVDH) was treated by intravenous injection of
ASCs [26-28]. This immunosuppressive role of ASCs
and their adjuvant effect in healing are also reflected in
the encouraging results which are being achieved in var-
ious clinical trials investigating ASCs transplantation for
treating fistula in patients with Crohn’s disease [29] and
radiotherapy-induced chronic ulcers [30].
Many other studies being conducted in animal models
show the potential of ASCs to regenerate cranial bone,
periodontal tissue and joint cartilage, in functional
repair of myocardial infarction, and in stroke [31,32].
Other types of stem cells
Hematopoietic stem cells together with mesenchymal
stem cells, the so-called “side population”, and multipo-
tent adult progenitor cells (MAPCs), are the stem cells
forming bone marrow [33]. Their role is maintenance
and turnover of blood cells and immune system.
The high rate of regeneration of the liver, as compared
to other tissues such as brain tissue, is due to prolifera-
tion of two types of liver cells, hepatocytes, and oval
cells (stem cells). In response to acute liver injuries
(hepatectomy or hepatotoxin exposure), hepatocytes
regenerate damaged tissue, while oval cells are activated
in pathological conditions where hepatocytes are not
able to divide (acute alcohol poisoning, phenobarbital
exposure, etc.), proliferating and converting into func-
tional hepatocytes [34].
In skeletal muscle, the stem cells, called satellite cells,
are in a latent state and are activated following muscle
injury to proliferate and differentiate into muscle tissue.
Muscle-derived stem cells have a greater ability for mus-
cle regeneration [35]. In cardiac tissue, cardiac progeni-
tor cells are multipotent and may differentiate both in
vitro and in vivo into cardiomyocytes, smooth muscle
cells, and vascular endothelial cells [36,37].
Neuronal stem cells able to replace damaged neurons
have been reported in the nervous system of birds, rep-
tiles, mammalians, and humans. They are located in the
dentate fascia of hippocampus and the subventricular
area of lateral ventricles [38,39]. Stem cells have also
recently been found in the peripheral nerve system (in
the carotid body) [40]. Astrocytes, which are glial cells,
have been proposed as multipotent stem cells in human
brain [41].
The high renewal capacity of the skin is due to the
presence in the epidermis of stem cells acting as a cell
reservoir. These include epidermal stem cells, mainly
located in the protuberance of hair follicle and which
are capable of self-renewal for long time periods and
differentiation into specialized cells, and transient ampli-
fying cells, distributed throughout basal lamina and
showing in vivo a very high division rate, but having a
lower differentiation capacity [42].
Induced pluripotent stem cells
Induced pluripotent stem cells (iPSCs) from somatic
cells are revolutionizing the field of stem cells. Obtained
by reprogramming somatic stem cells of a patient
through the introduction of certain transcription factors
[43-48], they have a potential value for discovery of new
drugs and establishment of cell therapy protocols
because they show pluripotentiality to differentiate into
cells of all three germ layers (endoderm, mesoderm, and
ectoderm).
The iPSC technology offers the possibility of develop-
ing patient-specific cell therapy protocols [49] because
use of genetically identical cells may prevent immune
rejection. In addition, unlike embryonic stem cells,
iPSCs do not raise a bioethical debate, and are therefore
a “consensus” alternative that does not require use of
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human oocytes or embryos [50]. Moreover, iPSCs are
not subject to special regulations [51] and have shown a
high molecular and functional similarity to embryonic
cells [52,53].
Highly encouraging results have been achieved with
iPSCs from skin fibroblasts, differentiated to insulin-
secreting pancreatic islets [54]; in lateral amyotrophic
sclerosis (Lou Gehrig disease) [55]; and in many other
conditions such as adenosine deaminase deficiency
combined with severe immunodeficiency, Shwachman-
Bodian-Diamond syndrome, type III Gaucher disease,
Duchenne and Becker muscular dystrophy, Parkinson
and Huntington disease, diabetes mellitus, or Down syn-
drome [56]. Good results have also been reported in
spinal muscular atrophy [57] and in screening tests in
toxicology and pharmacology, for toxic substances for
the embryo or for teratogenic substances [58].
A very recent application has been reported by
Moretti et al. [59] in the long QT syndrome, a hereditary
disease associated to prolongation of the QT interval and
risk of ventricular arrhythmia. iPCSs retain the genotype
of type 1 disease and generate functional myocytes
lacking the KCNQ1 gene mutation. Patients show nor-
malization of the ventricular, atrial, and nodal phenotype,
and positively express various normal cell markers.
Stem cell therapy: A new concept of medical application
in Pharmacology
For practical purposes, human embryonic stem cells are
used in 13% of cell therapy procedures, while fetal stem
cells are used in 2%, umbilical cord stem cells in 10%,
and adult stem cells in 75% of treatments. To date, the
most relevant therapeutic indications of cell therapy
have been cardiovascular and ischemic diseases, dia-
betes, hematopoietic diseases, liver diseases and, more
recently, orthopedics [60]. For example, more than
25,000 hematopoietic stem cell transplantations
(HSCTs) are performed every year for the treatment of
lymphoma, leukemia, immunodeficiency illnesses, con-
genital metabolic defects, hemoglobinopathies, and mye-
lodysplastic and myeloproliferative syndromes [61].
Depending on the characteristics of the different ther-
apeutic protocols and on the requirements of each con-
dition, each type of stem cell has its advantages and
disadvantages. Thus, embryonic stem cells have the
advantages of being pluripotent, easy to isolate, and
highly productive in culture, in addition to showing a
high capacity to integrate into fetal tissue during devel-
opment. By contrast, their disadvantages include
immune rejection, the possibility that they differentiate
into inadequate cell types or induce tumors, and con-
tamination risks. Germ stem cells are also pluripotent,
but the source from which they are harvested is scarce,
and they may develop embryonic teratoma cells in vivo.
Adult stem cells are multipotent, have a greater differen-
tiation potential, less likely to induce no immune rejec-
tion reactions, and may be stimulated by drugs. Their
disadvantages include that they are scarce and difficult
to isolate, grow slowly, differentiate poorly in culture,
and are difficult to handle and produce in adequate
amounts for transplantation. In addition, they behave
differently depending on the source tissue, show telo-
mere shortening, and may carry the genetic abnormal-
ities inherited or acquired by the donor.
These disadvantages of adult stem cells are less
marked in some of the above mentioned subtypes, such
as mesenchymal stem cells obtained from bone marrow
or adipose tissue, or iPSCs. In these cases, harvesting
and production are characterized by their easiness and
increased yield rates in the growth of the cultures. Their
growth is slow but meets experimental requirements,
and their differentiation and implantation are highly
adequate [62,63].
Overall, at least three types of therapeutic strategies
are considered when using stem cells. The first is stimu-
lation of endogenous stem cells using growth factors,
cytokines, and second messengers, which are able to
induce self-repair of damaged tissues or organs. The
second alternative is direct administration of stem cells
so that they differentiate at the damaged or non-func-
tional tissue sites. The third possibility is transplantation
of cells, tissues, or organs taken from cultures of stem
cell-derived differentiated cells.
The US Food and Drug Administration defines
somatic cell therapy as the administration of autologous,
allogeneic, or xenogeneic non-germ cells–excluding
blood products for transfusion–which have been
manipulated or processed and propagated, expanded,
selected ex vivo, or drug-treated.
Cell therapy applications are related to the treatment
of organ-specific diseases such as diabetes or liver dis-
eases. Cell therapy for diabetes is based on islet trans-
plantation into the portal vein of the liver and results in
an improved glucose homeostasis, but graft function is
gradually lost in a few years after transplantation. Liver
diseases (congenital, acute, or chronic) may be treated
by hepatocyte transplantation, a technique under devel-
opment and with significant disadvantages derived from
difficulties in hepatocyte culture and maintenance. The
future here lies in implantation of hepatic stem cells, or
in implantation of hepatic cells obtained by differentia-
tion of a different type of stem cell, such as mesenchy-
mal stem cells.
Other applications, still in their first steps, include
treatment of hereditary monogenic diseases such as
hemophilia using hepatic sinusoidal endothelial cells
[64] or murine iPSCs obtained by fibroblast differentia-
tion into endothelial cells or their precursors [65].
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As regards hemophilia, an optimum candidate because it
is a monogenic disease and requires low to moderate
expression levels of the deficient coagulation factor to
achieve a moderate phenotype of disease, great progress
is being made in both gene therapy and cell therapy
using viral and non-viral vectors. The Liras et al. group
has reported encouraging preliminary results using non-
viral vectors and mesenchymal stem cells derived from
adult human adipose tissue [66-68].
Very recently, Fagoonee et al. [69] first showed that
adult germ line cell-derived pluripotent stem cells
(GPSCs) may differentiate into hepatocytes in vitro,
which offers a great potential in cell therapy for a very
wide variety of liver diseases.
Histocompatible stem cell therapy
Since one of the most important applications of cell
therapy is replacement of the structure and function of
damaged or diseased tissues and organs, avoidance or
reduction of rejection due to a natural immune response
of the host to the transplant is a highly relevant consid-
eration. Recent progress in nuclear transference from
human somatic cells, as well as the iPSC technology,
have allowed for availability of lineages of all three germ
layers genetically identical to those of the donor patient,
which permits safe transplantation of organ-tissue-speci-
fic adult stem cells with no immune rejection [70].
On the other hand, adipose-derived mesenchymal
stem cells (ASCs) are able to produce adipokines,
including many interleukines [71]. ASCs also have
immunosuppressive capacity, regulating inflammatory
processes and T-cell immune response [72-74]. The lack
of HLA-DR expression and immunosuppressive proper-
ties of ASCs make these cells highly valuable in allo-
geneic transplantation to prevent tissue rejection. They
do not induce alloreactivity in vitro with incompatible
lymphocytes and suppress the antigen response reaction
by lymphocytes. These findings support the idea that
ASCs share immunosuppressive properties with bone
marrow-derived MSCs and may therefore represent a
new alternative for conditions related to the immune
system [75-77].
Suitability of infrastructure and technical staff
Any procedure related to cell therapy requires a strict
control of manipulation and facilities. In addition, it
should not be forgotten that cell therapy products are
considered as drugs, and the same or a similar type of
regulation should therefore be followed for them.
Products must be carefully detailed and described,
stating whether autologous, allogeneic, or xenogeneic
cells are administered. Xenogeneic cells are included by
the US Food and Drug Administration [78] as human
cells provided there has been ex vivo contact with living
non-human cells, tissues, or organs. It should also be
detailed whether cells have been manipulated together
with other non-cell materials such as synthetic or nat-
ural biomaterials, with other types of materials or agents
such as growth factors or serum.
As regards the production process, a detailed descrip-
tion must be given of all procedures related to product
quality in the Standard Operating Procedures (SOPs), as
for conventional medical products. The purity, safety,
functionality, and identity criteria used for conventional
drugs must be met.
Because of the characteristics of these products, their
storage period before sale or distribution should necessa-
rily be shorter, as they cannot obviously be subject to
prior sterilization (hence the use of cryopreservation as
the most adequate storage method). Therefore, the pro-
duction process must occur in a highly aseptic environ-
ment with comprehensive controls of both raw materials
and handlers. Needless to say that production process
should be highly reproducible and validated both on a
small scale for a single patient and on a large scale. For
an autologous therapy procedure, cell harvesting from
the patient will be aimed at collecting healthy cells when-
ever this is possible, because in some cases, if no mosai-
cism exists and the disease is inherited, all cells will carry
the relevant mutation, in which case this procedure will
not be feasible. In hemophilia the situation may be favor-
able, because mosaicism is found in 30% of the cases [79].
Cell therapy products should adhere to the Current
Good Manufacturing Practices, including quality control
and quality assurance programs, which establish mini-
mum quality requirements for management, staff, equip-
ment, documentation, production, quality control,
contracting-out, claims, product recall, and self-inspec-
tion. Production and distribution should be controlled by
the relevant local or national authorities based on the
International Conference on Harmonization of Pharma-
ceuticals for Human Use, which standardizes the poten-
tial interpretations and applications of the corresponding
recommendations [80].
It is of paramount importance to prevent potential
contamination, both microbiological and by endotoxins,
due to defects in environmental conditions, handlers,
culture containers, or raw materials, or crossed contami-
nation with other products prepared at the same pro-
duction plant. Care should be taken with methods for
container sterilization and control of raw materials and
auxiliary reagents, use of antibiotics, use of High Effi-
ciency Particulate Absorbing (HEPA) filters to prevent
airborne cross-contamination, separate handling of
materials from different patients, etc.
In compliance with official standard books such as the
European Pharmacopoeia (Eur.Ph.) [81] or the United
States Pharmacopeia (USP) [82], each batch of a biologi-
cal product should pass a very strict and specific test
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depending on the characteristics of the cell therapy pro-
duct, such as colorimetry, oxygen consumption, or PCR.
Facilities where products are handled, packaged, and
stored should be designed and organized according to
the guideline Good Manufacturing Practice for Pharma-
ceutical Manufacturers (GMP) [83]. The most important
rooms of these facilities include the so-called clean
rooms, which are classified in four classes (A-D) depend-
ing on air purity, based on the number of particles of
two sizes (≥ 0.5 μm, ≥ 5 μm). Other parameters such as
temperature, humidity, and pressure should be taken
into account and monitored because of their potential
impact on particle generation and microorganism
proliferation.
As regards to the number of technical staff, this
should be the minimum required and should be espe-
cially trained in basic hygiene measures required for
manipulation in a clean room. Material and staff flows
should be separated and be unidirectional to minimize
cross contamination, and control and documentation of
all activities is necessary. Technical staff should have
adequate qualification both for the conduct and surveil-
lance of all activities.
Good Manufacturing Practice for Pharmaceutical
Manufacturers is a general legal requirement for all bio-
logical medicinal products before their marketing or dis-
tribution. As in tissue donation, use of somatic cells
from a donor requires the method to be as least invasive
as possible and to be always performed after obtaining
signed informed consent. In this regard, risk-benefit
assessment in this field is even more necessary in this
field than in other areas because of the sometimes high
underlying uncertainty when stem cells are used [84].
Biomaterials for Cellular Therapy
In advanced therapies, particularly in cell therapy and
tissue engineering, the biomaterial supporting the biolo-
gical product has a similar or even more important role
as the product itself. Such biomaterials serve as the
matrix for nesting of implanted cells and tissues because
they mimic the functions of the tissue extracellular
matrix.
Biomaterials for cell therapy should be biocompatible
to prevent immune rejection or necrosis. They should
also be biodegradable and assimilable without causing
an inflammatory response, and should have certain
structural and mechanical properties. Their primary role
is to facilitate location and distribution of somatic cells
into specific body sites–in much the same way as excipi-
ents in classical pharmacology–and to maintain the
three-dimensional architecture that allows for formation
and differentiation of new tissue.
Materials may be metals, ceramic materials, natural
materials, and synthetic polymers, or combinations
thereof. Synthetic polymers are biocompatible materials
(although less so than natural materials) whose three-
dimensional structure may easily and reproducibly be
manufactured and shaped. Their degradation rate may
be controlled, they are free from pathogens, and bioac-
tive molecules may be incorporated into them. Their
disadvantage is that they may induce fibrous encapsula-
tion. Natural polymers such as collagen, alginate, or ker-
atin extracts are also biocompatible and, as synthetic
polymers, may be incorporated active biomolecules.
They have however the disadvantages that they may
mimic the natural structure and composition of extra-
cellular matrix, their degradation rate is not so easy to
control, have less structural stability, are sensitive to
temperature, and may be contaminated by pathogens.
In any case, use of one or the other type of biomater-
ial is always related to the administration route in cell
therapy protocols, implantation or injection. Thus, in
the injection-based procedure, which is simpler and
requires no surgery but can only be used for certain
areas, biomaterials are usually in a hydrogel state, form-
ing a hydrophilic polymer network, as occurs in PEO
(polyethylene oxide), PVA (polyvinyl alcohol), PAA (poly-
acrylic acid), agarose, alginate, collagen, and hyaluronic
acid.
Research on biomaterials for cell therapy is aimed not
only at finding or synthesizing new materials, but also at
designing methods that increase their efficacy [85]. For
example, control of the porous structure of these mate-
rials is very important for increasing their efficacy in tis-
sue regeneration (through solvent casting/particulate
leaching, freeze-drying, fiber bonding, electrospinning,
melt molding, membrane lamination, or hydrocarbon
templating). An attempt may also be made to increase
biocompatibility through chemical (oxidation or hydro-
lysis) or physical modification. To increase cell adhesion
and protein adsorption, water-soluble polymers may be
added to the biomaterial surface. Bioactive molecules
such as enzymes, proteins, peptides, or antibodies may
also be coupled, as is the standard and routine practice,
to the biomaterial surface to provide it with functional-
ity. Other substances such as cytokines or growth fac-
tors which promote migration, proliferation, or overall
function of cells used in therapy may be coupled.
Another highly relevant line of research aims at mini-
mizing immune rejection when cells to be used are not
autologous cells. Immunoisolation by cell microencapsu-
lation (coating of biologically active products by a poly-
mer matrix surrounded by a semipermeable membrane),
which allows for two-directional substance diffusion, is
extremely important and is giving optimal results
[86-89].
Many types of biomaterials are being developed for
bone tissue regeneration based on either demineralized
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bone matrix or in bladder submucosa matrix combined
with poly(lactic-co-glycolic acid) (PLGA), which acceler-
ates regeneration and promotes cell accommodation in
in vivo bone formation [90,91]. For bypass procedures in
large-diameter vessels, synthetic polymers such as
expanded polytetrafluoroethylene (ePTFE) or polyethy-
lene terephthalate (PET) fiber have been applied [92].
For peripheral nerve repair, use of axonal guides made
of several materials such as silicone, collagen, and PLGA
[93], and recently of Schwann cells to accelerate axonal
regeneration, have been reported [94].
Advances in identification of the optimal characteris-
tics of the matrix and an increased understanding of
interactions between cells and biomaterials will condi-
tion development of future cell therapy protocols.
Production costs, biobanks and biosecurity in cell therapy
Production costs in cell therapy are high (currently, a
treatment may cost more than 40,000 dollars), mainly
because drug products based on cell therapy are pre-
pared on a low and almost individual scale, but allo-
geneic procedures [95] and availability of cryopreserved
cell banks (biobanks) will lead cell therapy to occupy a
place in the market of future pharmacology.
Costs are accounted for by different items, all of them
necessary, including multiple surgical procedures, main-
tenance of strict aseptic conditions, specific training of
technical staff and maintenance of overall technical and
staff support, specialized facilities, the need for produ-
cing small and highly unstable batches and, of course,
design and development of the different market strate-
gies. The question arises as to whether these costs will
be compatible with at least partial funding by govern-
ments, medical insurance companies, and public and
private health institutions, and with current and future
demographic movements ("demographic” patients) [96].
Until widespread use of allogeneic protocols becomes
established, thus overcoming the problems derived from
immune rejection, and although it is not certain if allo-
geneic cell transplantation will ever be free from clinical
complications, biobanks represent the hope for the pro-
ject of cell therapy to become a reality in the future
[97]. Concerning production costs, even if biobanks
exist, the production of cellular therapies often require
the use of cytokines, growth factors and specialized
reagents which are very expensive.
Stem cell banks [98] store lines of embryonic and
adult human stem cells for purposes related to biomedi-
cal research. Regardless of their public (nonprofit, anon-
ymous donation) or private (donation limited to a
client’s environment) nature, stem cell banks may store
cell lines from umbilical cord and placental tissue, rich
in hematopoietic stem cells, or cell lines derived from
various somatic tissues, either differentiated or not.
There are banks of cryopreserved umbilical cord bloods
throughout Europe and North America. These were set
up primarily for hematopoietic stem cell transplantation,
but they are available for other clinical uses.
Two of the most relevant international banks are the
US National Stem Cell Bank (NSCB) [99] and the
United Kingdom Stem Cell Bank [100].
The NSCB was set up at the WiCell Research Institute
on September 2005 and is devoted to acquisition, char-
acterization, and distribution of 21 embryonic stem cell
lines and their subclones for use in research programs
funded by the National Institute of Health (NIH), and to
provide the research community with adequate technical
support. The UKSCB was created on September 2002 as
an independent initiative of the Medical Research Coun-
cil (MRC) and the Biological Sciences Research Council
(BBSRC), and serves as a storage facility for cell lines
from both adult and embryonic stem cells which are
available for use in basic research and in development
of therapeutic applications.
Culture of adult stem cells, which are safer to use,
must be kept in culture since they are harvested until
they are used. This may involve risks of contamination
or pseudodifferentition leading to a loss of biological
specificity of each target cell population in its physiolo-
gical interaction with all other tissues. This makes it
essential, for biosafety purposes, to assess and monitor
any ex vivo differentiation procedure, first in vitro cul-
tures and then in animal models, to verify the properties
of the stem cell and its genetic material and to prevent
risks, which may range from tumor formation to simple
uncertainty about its differentiation [101].
If the biological material is human embryonic stem
cells (hES), there is no standard method for characteri-
zation, but some of their specific characteristics may be
assessed, including the nucleus-cytoplasm ratio, number
of nucleoli and morphological characteristics of the col-
ony, growth rate, percent clonogenicity, in vitro embry-
oid body formation, and in vitro teratoma formation
after subcutaneous implantation in immunodeficient
mice. Clinical use of this type of cells always requires
control of their in vitro differentiation into multipotent
or fully differentiated cells with tumorogenic potential.
The cell characterization process in molecular and cellu-
lar terms is time-consuming and takes some years, espe-
cially as regards self-renewal pathways and development
potential, which are very different in humans and mur-
ine models.
Control of cell transformation is particularly important
for biosecurity of cell therapy products. Hematopoietic
stem cells are extremely resistant to transformation due
to two types of control, replicative senescence (phase
M1) and cell crisis (phase M2). Cell senescence is
usually induced by a moderate telomere shortening or
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by oncogene expression leading to morphological
changes such as cell lengthening or a change in expres-
sion of specific senescence markers. The cell crisis
phase occurs when some cell types avoid this control
until telomeres become critically short, chromosomes
become unstable, and apoptosis is activated. Sponta-
neous transformations have been reported in human
(hMSCs) and murine (mMSCs) mesenchymal stem cells
[102], suggesting that extreme caution is required when
these cells are used in clinical treatments. However, it
should also be noted that cell transformation occurs
after a long time period (4 months), much longer than
the culture periods of therapeutic cells (2-14 passages;
1-8 weeks), which is the minimum and almost sufficient
time to obtain an adequate number of cells for a cell
therapy treatment, and during which the senescence
phenomenon is less likely.
Biotechnological industry
Stem cell research is in its early stages of development,
and the market related to cell therapy is therefore highly
immature, but the results achieved to date raise great
expectations.
In order to analyze the current status and perspectives
of this particular market, a distinction should be made
between embryonic and adult stem cells, because the
number of companies in these two fields is very differ-
ent (approximately 30-40 working with adult versus
8-10 working with embryonic stem cells). Such differ-
ence is mainly due to ethical and legal issues associated
to each cell type or to the disparity of criteria between
the different countries regarding the industrial and even
intellectual properties of the different technologies
derived from stem cell research.
Overall, the potential numbers of patients who could
benefit from cell therapy in the US would be approxi-
mately 70 million patients with cardiovascular disease,
50 millions with autoimmune diseases, 18 millions with
diabetes, 10 millions with cancer, 4.5 millions with Alz-
heimer’s disease, 1 million with Parkinson’s disease, 1.1
millions with burns and wounds, and 0.15 millions with
medullary lesions (data taken from Advanced Cell Tech-
nology [103].
Today, many pharmaceutical companies, including the
big ones, are reluctant to enter this market because of
the great investment required and because a very hard
competition is expected in the pharmaceutical market.
To date, the most profitable strategy has been the sign-
ing of agreements between big pharmaceutical compa-
nies and other small biotechnological companies whose
activity is 100% devoted to cell therapy and regenerative
medicine.
Special mention should be made of induced pluripo-
tent stem cells (iPSCs), which have raised great expecta-
tions in the pharmaceutical industry because products
to be derived from them, as noted above, will be applic-
able in a very wide range of development of new drugs
and new procedures for the treatment of a great number
of human diseases. At least 5-10 years will elapse until
these products, not therapeutic yet and under study, are
in therapeutic use and yield an economic return to bio-
technological companies. Today, this interesting poten-
tial of therapeutic products derived from iPSCs still
faces great technical and scientific challenges, and a very
long time will be required until they fulfill their promise.
Overall, business models for marketing must be well
devised and optimized, and also very well tested and
based on accumulated experience with the various types
of both adult and embryonic or induced stem cells
[104].
Research perspectives of stem cells
The general objectives in the area of stem cell research
in the next few years, are related to identification of
therapeutic targets and potential therapeutic tests.
Within these general objectives, other specific objectives
will be related to studies of cell differentiation and cellu-
lar physiological mechanisms that will enhance under-
standing, prevention, and treatment of some congenital
or acquired defects. Other objectives would be to estab-
lish the culture conditions of pluripotent stem cells
using reliable cytotoxicity tests and the optimum type of
cell or tissue to be transplanted depending on the dis-
ease to be treated (bone marrow for leukemia and che-
motherapy; nerve cells for treating conditions such as
Parkinson and Alzheimer diseases; cardiac muscle cells
for heart diseases, or pancreatic islets for the treatment
of diabetes.
The current reality is that, although extensive research
is ongoing and encouraging partial results are being
achieved, there is still much to be known about the
mechanisms of human development and all differentia-
tion processes involved in the whole process from fertili-
zation to the full development of an organism. In this,
which appears so simple, lies the “mystery” surrounding
differentiation of the different stem cells and the many
factors that condition it.
A second pending question, is the efficacy and safety
tests for stem cell-based drugs or procedures to be per-
formed in both animal and human models in the corre-
sponding phase I-III clinical trials.
The final objective of stem cell research is to “cure”
diseases. Theoretically, stem cell therapy is one of the
ideal means to cure almost all human diseases known,
as it would allow for replacing defective or dead cells by
normal cells derived from normal or genetically modi-
fied human stem cell lines [105].
If, as expected, such practices are possible in the
future, stem cell research will shift the paradigm of
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medical practice. Some scientists and healthcare profes-
sionals think, for example, that Parkinson’s disease,
spinal cord injury, and type 1 diabetes [106] may be the
first candidates for stem cell therapy. In fact, the US
Food and Drug Administration has already approved the
first clinical trial of products derived from human
embryonic stem cells in acute spinal cord injuries
[107,108].
Human stem cells, mainly autologous bone marrow
cells, autologous and allogeneic mesenchymal cells, and
some allogeneic neural cells, are currently being assessed
in various clinical studies. As regards transplantation of
bone marrow and mesenchymal cells, many data show-
ing its safety are already available, while the efficacy
results reported are variable. The most convincing likely
explanation for this is that many mechanisms of action
of these cells are not known in detail, which makes
results unpredictable. Despite this, there is considerable
optimism based on the immune suppression induced by
mesenchymal stem cells and on their anti-inflammatory
properties, which may be beneficial for many conditions
such as graft-versus-host disease, solid organ transplan-
tation, and pulmonary fibrosis. Variable results have
been reported after use of mesenchymal stem cells in
heart diseases, stroke, and other neurodegenerative dis-
orders, but no significant effects were seen in most
cases. By contrast, encouraging results were found in
the correction of multiple sclerosis, at least in the short
term. Neural stem cells may be highly effective in inop-
erable glioma, and embryonic stem cells for regeneration
of pancreatic beta cells in diabetes [109].
The change in policy regarding research with embryo-
nic stem cells by the Obama administration, which her-
alds a change of environment leading to an increased
cooperation in the study and evaluation of stem cell
therapies, opens up new and better expectations in this
field. The initiative by the California Institute for Regen-
erative Medicine [110] has resulted in worldwide colla-
boration for these new drugs based on stem cells [111].
Thus, active participation of governments, research aca-
demies and institutes, pharmaceutical and biotechnolo-
gical companies, and private investment may shape a
powerful consortium that accelerates progress in this
field to benefit of health.
Legal and regulatory issues of cell therapy
Cell therapy is one of the advanced therapy products
(ATPs), together with gene therapy and tissue engineer-
ing. A regulatory framework is required for ATPs to
ensure patient accessibility to products and governmen-
tal assistance for their regulation and control. Certainty,
scientific reality and objectivity, and flexibility to keep
pace with scientific and technological evolution are the
characteristics defining an effective regulation.
Aspects to be regulated mainly include control of
development, manufacturing, and quality using release
and stability tests; non-clinical aspects such as the need
for studies on biodistribution, cell viability and prolifera-
tion, differentiation levels and rates, and duration of in
vivo function; and clinical aspects such as special dose
characteristics, stratification risk, and specific pharma-
covigilance and traceability issues.
European Medicines Agency: Regulation in the European
Union
European countries may be classified into three groups
based on their different positions regarding research
with embryonic stem cells of human origin. i) Countries
with a restrictive political model (Iceland, Lithuania,
Denmark, Slovenia, Germany, Ireland, Austria, Italy,
Norway, and Poland); ii) Countries with a liberal politi-
cal model (Sweden, Belgium, United Kingdom, and
Spain); and iii) Countries with an intermediate model
(Latvia, Estonia, Finland, France, Greece, Hungary, Swit-
zerland, the Netherlands, Bulgaria, Cyprus, Portugal,
Turkey, Ukraine, Georgia, Moldavia, Romania, and
Slovakia).
The Seventh Framework Program for Research of the
European Union, coordinated by the European Medi-
cines Agency, was approved on July 2006 [112]. This
Seventh Framework Program provides for funding of
research projects with embryonic stem cells in countries
where this type of research is legally accepted, and the
projects involving destruction of human embryos will
not be financed with European funds. Guidelines on
therapeutic products based on human cells are also
established [113].
This regulation replaces the points in the prior 1998
regulation (CPMP/BWP/41450/98) referring to the man-
ufacture and quality control of therapy with drugs based
on human somatic cells, adapting them to the applicable
law and to the heterogeneity of products, including
combination products. Guidance is provided about the
criteria and tests for all starting materials, manufactur-
ing process design and validation, characterization of
cell-base medicinal products, quality control aspects of
the development program, traceability and vigilance, and
comparison. Is also provides specific guidance of
matrixes and stabilizing and structural devices or pro-
ducts as combination components.
The directive recognizes that conventional non-clinical
pharmacology and toxicological studies may be different
for cell-based drugs, but should be strictly necessary for
predicting response in humans. It also establishes the
guidelines for clinical trials as regards pharmacodynamic
and pharmacokinetic studies, defining the clinically
effective safe doses. The guideline describes the special
consideration to be given to pharmacovigilance issues
and the risk management plan for these products.
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The guideline has therefore a multidisciplinary nature
and addresses development, manufacture, and quality
control, as well as preclinical and clinical development
of medicinal products based on somatic cells (Directive
2001/83/EC) and tissue engineering products (Regula-
tion 1394/2007/EC2). Includes autologous or allogeneic
(but not xenogeneic) protocols based on cells either iso-
lated or combined with non-cell components, or geneti-
cally modified. However, the document does not address
non-viable cells or fragments from human cells.
Legislation on cell therapy in Europe is based on three
Directives: Directive 2003/63/EC (amending Directive
2001/83/EC), which defines cell therapy products as
clinical products and includes their specific require-
ments; Directive 2001/20/EC, which emphasizes that
clinical trials are mandatory for such products and
describes the special requirements for approval of such
trials; and Directive 2004/23/EC, which establishes the
standard quality, donation safety, harvesting, tests, pro-
cessing, preservation, storage, and distribution of human
tissues and cells.
The marketing authorization application has been pre-
pared by the European Medicines Agency so that cell
therapy products should meet the same administrative
and scientific requirements as any other drug [114].
US Food and Drug Administration (FDA): Regulation in the
United States of America
In the United States of America, restrictions are limited
to research with federal funds. No limitations exist for
research with human embryonic stem cells provided the
funds come from private investors or specific states. In
countries such as Australia, China, India, Israel, Japan,
Singapore, and South Korea, therapeutic cloning is
permitted.
The FDA has developed a regulatory framework that
controls both cell- and tissue-based products, based on
three general areas: i) Prevention of use of contaminated
tissues or cells (e.g. AIDS or hepatitis); ii) prevention of
inadequate handling or processing that may damage or
contaminate those tissues or cells; and iii) clinical safety
of all tissues or cells that may be processed, used for
functions other than normal functions, combined with
components other than tissues, or used for metabolic
purposes. The FDA regulation, derived from the 1997
basic document “Proposed approach to regulation of cel-
lular and tissue-based products” [115]. The FDA has
recently issued updates to previous regulations referring
to human cells, tissues, and all derived products [116].
This regulation provides an adequate regulatory struc-
ture for the wide range of stem cell-based products
which may be developed to replace or repair damaged
tissue, as both basic and clinical researchers and those
working in biotechnological and pharmaceutical compa-
nies which need greater understanding and information
to answer many questions before submitting a stem cell-
based product for clinical use.
It should be reminded that, unlike conventional med-
icinal products, many stem cell-derived products are
developed at universities and basic research institutions,
where preclinical studies are also conducted, and that
researchers there may not be familiar with the applic-
able regulations in this field. The FDA also provides
specific recommendations on how scientists should
address the safety and efficacy issues related to this type
of therapies [117].
Any product based on stem cells or tissues undergoes
significant processing, and it should therefore be fully
verified that they retain their normal physiological func-
tion, either combined or not with other non-tissue com-
ponents, because they will generally be used for
metabolic purposes [116,118]. This is why many such
products, if not all, must also comply with the Public
Health Services Act, Section 351, governing the granting
of licenses for biological products, which requires FDA
submission and application for investigational protocols
of new drugs before conducting clinical trials in
humans.
The key points of the current FDA regulation for cell
therapy products [117] include: i) demonstration of pre-
clinical safety and efficacy; ii) no risk for donors of
transmission of infectious or genetic diseases; iii) no risk
for recipients of contamination or other adverse effects
of cells or sample processing; iv) specific and detailed
determination of the type of cells forming the product
and what are their exact purity and potency; v) in vivo
safety and efficacy of the product.
There is still much to be learned about the procedures
to establish the safety and efficacy of cell therapy pro-
ducts. The greater the understanding of the biology of
stem cell self-renewal and differentiation, the more pre-
cise the evaluation and prediction of potential risks.
Development of techniques for cell identification within
a mixed cell culture population and for follow-up of
transplanted cells will also be essential to ascertain the
potential in vivo invasive processes and to ensure safety.
Since new stem cell-based therapies develop very fast,
the regulatory framework must be adapted and evolve
to keep pace with such progress, although it may be
expected to change more slowly. Meanwhile, the current
regulations must provide the framework for ensuring
the safety and efficacy of the next generations of stem
cell-based therapeutic products.
Bioethical aspects of cell therapy
Ethics is not in itself a discipline within human knowl-
edge, but a “dialogue” where each person, from his/her
stance, gives his/her opinion and listens to the other
person’s opinion.
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Most cell therapy protocols have not been controver-
sial. The exception is therapy with human embryonic
stem cells, which has raised moral and ethical issues
[119,120]. Such considerations refer to donor consent
and problems associated to oocyte collection and the
issue of destruction of human embryos [121].
Guidelines–ranging from total prohibition to con-
trolled permissiveness–defining what may be permitted
in research with pluripotent stem cells have been issued
in countries all over the world [122].
All such guidelines reflect the different views about
when life starts during the human embryonic develop-
ment, as well as regulation of measures to protect
oocyte donors and to reduce the probability of human
embryo destruction [123].
There is general international agreement in that the
results of stem cell research should not be applied in
humans without prior ethical scrutiny. For this purpose,
42 European countries have national ethics committees
since 2006, and a President’s Council on Bioethics with
an advisory role in bioethical matters was created in the
US in 2001. The European Commission currently has
the Group on Ethics in Science and New Technologies,
an advisory, independent, and plural multidisciplinary
body [124], and in other countries, such as the United
Kingdom, legislation on action and bioethics is clearly
established since several years ago [125].
The Ethics and Health Team at World Health Organi-
zation [126] acts as a permanent secretariat for the Glo-
bal Summit of National Bioethics Commissions and
cooperates with the European Conference of National
Ethics Committees (COMETH) [127]. On the other
hand, the UNESCO created in 1992 the International
Bioethics Committee [128].
In the United States, the National Institute of Health
provides detailed and updated information on various
aspects related to stem cells [129] in order to educate
and update on the different viewpoints on bioethical
issues as a function of progress in science and technol-
ogy related to the field of cell therapy.
The National Academy of Sciences issued in 2005 its
first set of ethical standards for stem cell research [130],
which were updated in 2007, 2008, and 2010, to adapt
the guidelines to rapid scientific and political advances,
by the Human Embryonic Stem Cell Research Advisory
Committee created in 2006 with the support of the Elli-
son Medical Foundation, The Greenwall Foundation,
and Howard Hughes Medical Institute. These updates
and amendments have updated the guidelines of the dif-
ferent national academies and take into account the new
role of the National Institute of Health with regard to
research with human embryonic stem cells.
The Presidential Commission on Bioethics for the
Study of Bioethical Issues advises President Obama on
any bioethical issues that may arise from advances in
biomedicine and in related areas of science and technol-
ogy [131]. This commission works to identify and
promote policies and practices ensuring ethically
responsible actions in scientific research, health care,
and technological innovation.
The Kennedy Institute of Ethics at Georgetown Univer-
sity Library and Information Services [132] allows for
searching books, newspapers, journal articles, and other
materials on bioethical issues. On the other hand, the
International Society for Stem Cell Research [133] and,
among others, the Bioethics Advisory Committee (BAC)
Singapore [134] have set up ethical, legal, and social reg-
ulations derived from research in biomedical sciences
and act as an advisory public service on stem cells.
In conclusion, scientists are aware of the need for
ethical evaluation of their research. This is discussed in
the Declaration on Science and the Use of Scientific
Knowledge of the 1999 World Conference on Science
held in Budapest, entitled Science for the Twenty-First
Century: a New Commitment attests to this awareness
[135]. This declaration states that scientific research and
use of scientific knowledge should respect human rights
and the dignity of human beings, in accordance with the
Universal Declaration of Human Rights and the Univer-
sal Declaration on the Human Genome and Human
Rights. The special responsibility of scientists for pre-
venting uses of science which are ethically incorrect or
have a negative impact for society is also established.
Commitments are established [136] to teach the next
generations of scientists that ethics and responsibility
are part of their daily training and work, and to warn
about any potential dilemmas that may arise in the
future with the inexorable progress of science.
There are two general basic issues related to bioethics
that should be considered with care and separately:
First, scientific and therapeutic relevance, and second,
the cost of cryopreservation over time. In term of rele-
vance, it should be considered that cells should be use-
ful for the treatment of a specific disease, but the exact
time of their use is not known, and they therefore have
to be cryopreserved. From a bioethical viewpoint, this is
more questionable when dealing with embryos whose
cryopreservation should be authorized by the parents
and which will be used either for a particular use or for
donation. These embryos may ultimately be used for
scientific uses of research with embryonic stem cells, in
which case the bioethical conflict may be further aggra-
vated. The second aspect is the cost of cryopreservation.
In some cases, such as preservation of umbilical cord
blood, private biobanks are mainly used today, which
may lead to a significant discrimination of people who
cannot afford payment for such banks as compared to
those who can.
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Although ethical issues are less questionable in the
case of adult stem cells as compared to embryonic stem
cells, the Council of Europe’s Steering Committee on
Bioethics [137] has prepared an additional protocol, in
the Convention on Human Rights and Biomedicine
[138], which represents a general ethical and legal fra-
mework for signatory countries. This document details
the different conditions, such as the prerequisite of
approval by an independent committee competent in
the corresponding field of a research project with both
adult and embryonic stem cells assessing the relevance
of the research purpose and the multidisciplinary
aspects from the bioethical viewpoint. Signature by the
donor, the research or hospital center, and the principal
investigator of the project of an informed consent that
explains in detail the potential risks and benefits and
informs on the rights and safeguards, is also established
as an indispensable condition.
Conclusions
In recent decades, a great interest has arisen in research
in the field of stem cells, which may have important
applications in tissue engineering, regenerative medicine,
and cell- and gene therapy. There is however much to
be investigated about the specific characteristics of effi-
cacy and safety of the new drugs based on this type of
cells.
Cell therapy is based on transplantation of live cells
into an organism in order to repair a tissue or restore
lost or defective functions. Recent studies have shown
that mesenchymal stem cells (MSCs) support hemato-
poiesis and immune response regulation and they repre-
sent an optimum tool in cell therapy because of their
easy in vitro isolation and expansion and their high
capacity to accumulate in sites of tissue damage, inflam-
mation, and neoplasia. On the other hand, adipose-
derived stem cells (ASCs) secrete many cytokines and
growth factors with anti-inflammatory, antiapoptotic,
and immunomodulatory properties. This makes these
stem cells optimum candidates for cell therapy. Induced
pluripotent stem cells (iPSCs) from somatic cells are
revolutionizing the field of stem cells. They have a
potential value for discovery of new drugs and establish-
ment of cell therapy protocols because they show pluri-
potentiality to differentiate into cells of all three germ
layers. The iPSC technology offers the possibility of
developing patient-specific cell therapy protocols
because use of genetically identical cells may prevent
immune rejection, and unlike embryonic stem cells,
iPSCs do not raise a bioethical debate, and are therefore
a “consensus” alternative that does not require use of
human oocytes or embryos.
Cell therapy applications are related to the treatment
of organ-specific diseases such as diabetes or liver
diseases. Another relevant application of cell therapy is
development of cancer vaccines based on dendritic cells
or cytotoxic T cells, in order to induce natural immu-
nity. Other applications, still in their first steps, include
treatment of hereditary monogenic diseases such as
hemophilia. Until widespread use of allogeneic protocols
becomes established, thus overcoming the problems
derived from immune rejection, biobanks represent the
hope for the project of cell therapy to become a reality
in the future; control of cell transformation is also parti-
cularly important for biosecurity of cell therapy
products.
Stem cell research is in its early stages of development,
and the market related to cell therapy is therefore highly
immature, but the results achieved to date raise great
expectations. Today, many pharmaceutical companies,
including the big ones, are reluctant to enter this market
because of the great investment required and because
very hard competition is expected in the pharmaceutical
market. The general objectives in this area in the next
few years, are related to identification of therapeutic tar-
gets and potential therapeutic tests. Within these general
objectives, other specific objectives will be related to stu-
dies of cell differentiation and cellular physiological
mechanisms that will enhance understanding, prevention,
and treatment of some congenital or acquired defects.
Other objectives would be to establish the culture condi-
tions of pluripotent stem cells using reliable cytotoxicity
tests and the optimum type of cell or tissue to be trans-
planted depending on the disease to be treated.
Up to now, most cell therapy protocols have not been
controversial. The exception is therapy with human
embryonic stem cells, which has raised moral and ethi-
cal issues. Such considerations refer to donor consent
and problems associated to oocyte collection and the
issue of destruction of human embryos. Guidelines–ran-
ging from total prohibition to controlled permissive-
ness–defining what may be permitted in research with
pluripotent stem cells have been issued in countries all
over the world.
Bioethical aspects will be required related to the scien-
tific and therapeutic relevance and cost of cryopreserva-
tion over time, but specially with respect to embryos
which may ultimately be used as source of embryonic
stem cells, in which case the bioethical conflict may be
further aggravated. Also, a regulatory framework will be
required to ensure patient accessibility to products and
governmental assistance for their regulation and control.
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